ARID2 and hepatocellular carcinoma: These mutations are usually frameshift and hemizygous, suggesting it may be a tumor suppressor, like ARID1A. More intriguing has been the discovery of ARID2 mutations in HCC (5.8%–6.5%), with strong enrichment in HCV-associated HCC (14%) (Fujimoto et al., 2012; Zhao et al., 2011).